CR rates in patients with r/r chronic lymphocytic leukemia (CLL) receiving CD19 CAR T cells were ≈ 30–50% [16, 17], with some remissions lasting beyond 6 years. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.